Last reviewed · How we verify
The Combination Therapy With Ra-223 and Enzalutamide (CORE-OCU)
This study is to evaluate preliminary efficacy of Ra-223 in combination with Enzalutamide in progressive CRPC patients with bone metastasis
Details
| Lead sponsor | Taro Iguchi, MD, PHD |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 10 |
| Start date | Fri Oct 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Mar 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Castration-resistant Prostate Cancer
- Bone Metastases
Interventions
- Ra-223 in combination with enzalutamide
Countries
Japan